Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venezuelan equine encephalitis virus DNA vaccine
- Development stage
- Phase 1
- Lead developer
- U.S. Army Medical Research Institute of Infectious Diseases
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The Venezuelan equine encephalitis virus (VEEV) DNA vaccine is a prophylactic genetic immunization designed to protect against infection by the mosquito-borne alphavirus VEEV. The most studied constructs encode the codon-optimized envelope glycoprotein genes or the full 26S structural gene region (C-E3-E2-6K-E1) of the IAB strain Trinidad donkey of VEEV. Delivered via intramuscular electroporation or jet injection, this DNA vaccine induces robust humoral and cellular immune responses in animal models and has advanced to Phase 1 human clinical trials. It elicits strong neutralizing antibody titers and Th1-type cellular immunity, providing complete protection from lethal aerosol challenge in mice and significant protection in non-human primates. The mechanism of action is based on expression of viral antigens from transfected host cells leading to an adaptive immune response targeting VEEV[1][3][4][5][6].
- Other names
- Venezuelan Equine Encephalitis DNA VaccineVEE virus DNA vaccine encoding 26S
02
Targets
VEEV E1 (Venezuelan equine encephalitis virus E1 glycoprotein)Venezuelan equine encephalitis virus E2 envelope glycoproteinVEEV envelope glycoprotein (Venezuelan equine encephalitis virus envelope glycoprotein)
Beyond the preview
Go deeper on Venezuelan equine encephalitis virus DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Venezuelan equine encephalitis virus DNA vaccine.